|117.26||+0.9600||+0.83%||Vol 765.81K||1Y Perf 38.11%|
|Sep 15th, 2021 16:00 DELAYED|
|- -%||- -|
|Target Price||163.60||Analyst Rating||Moderate Buy 2.09|
|Potential %||39.52||Finscreener Ranking||★★★★★ 62.37|
|Insiders Trans % 3/6/12 mo.||-100/-100/-100||Value Ranking||★★★★★ 63.86|
|Insiders Value % 3/6/12 mo.||-100/-100/-100||Growth Ranking||★★★★★ 85.15|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-100/-100||Income Ranking||— -|
|Price Range Ratio 52W %||26.94||Earnings Rating||Strong Sell|
|Market Cap||8.94B||Earnings Date||27th Oct 2021|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Sell|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||27th Oct 2021|
|Estimated EPS Next Report||-1.68|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||834.06K|
|Avg. Monthly Volume||846.07K|
|Avg. Quarterly Volume||1.24M|
CRISPR Therapeutics AG (NASDAQ: CRSP) stock closed at 117.26 per share at the end of the most recent trading day (a 0.83% change compared to the prior day closing price) with a volume of 773.54K shares and market capitalization of 8.94B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 410 people. CRISPR Therapeutics AG CEO is Samarth Kulkarni.
The one-year performance of CRISPR Therapeutics AG stock is 38.11%, while year-to-date (YTD) performance is -23.41%. CRSP stock has a five-year performance of %. Its 52-week range is between 79.31 and 220.2, which gives CRSP stock a 52-week price range ratio of 26.94%
CRISPR Therapeutics AG currently has a PE ratio of 23.70, a price-to-book (PB) ratio of 3.53, a price-to-sale (PS) ratio of 9.97, a price to cashflow ratio of 16.60, a PEG ratio of 2.32, a ROA of 22.31%, a ROC of 23.78% and a ROE of 25.06%. The company’s profit margin is 50.71%, its EBITDA margin is 50.90%, and its revenue ttm is $901.76 Million , which makes it $11.83 revenue per share.
Of the last four earnings reports from CRISPR Therapeutics AG, there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-1.68 for the next earnings report. CRISPR Therapeutics AG’s next earnings report date is 27th Oct 2021.
The consensus rating of Wall Street analysts for CRISPR Therapeutics AG is Moderate Buy (2.09), with a target price of $163.6, which is +39.52% compared to the current price. The earnings rating for CRISPR Therapeutics AG stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
CRISPR Therapeutics AG has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
CRISPR Therapeutics AG has a Sell technical analysis rating based on Technical Indicators (ADX : 24.51, ATR14 : 5.07, CCI20 : -142.17, Chaikin Money Flow : -0.19, MACD : -2.27, Money Flow Index : 22.63, ROC : -5.29, RSI : 41.05, STOCH (14,3) : 18.83, STOCH RSI : 0.27, UO : 33.34, Williams %R : -81.17), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of CRISPR Therapeutics AG in the last 12-months were: Bradley J. Bolzon (Sold 520 292 shares of value $76 953 403 ), James R. Kasinger (Option Excercise at a value of $1 715 969), James R. Kasinger (Sold 27 500 shares of value $5 635 943 ), Lawrence Otto Klein (Option Excercise at a value of $3 041 275), Lawrence Otto Klein (Sold 125 000 shares of value $18 185 179 ), Michael J. Tomsicek (Option Excercise at a value of $443 750), Michael J. Tomsicek (Sold 25 000 shares of value $3 462 926 ), Michael Tomsicek (Option Excercise at a value of $0), Rodger Novak (Option Excercise at a value of $1 082 250), Rodger Novak (Sold 150 000 shares of value $20 004 207 ), Samarth Kulkarni (Option Excercise at a value of $474 478), Samarth Kulkarni (Sold 70 000 shares of value $10 911 896 ), Tony W. Ho (Option Excercise at a value of $398 012), Tony W. Ho (Sold 23 551 shares of value $3 514 610 )
Copyright © 2016-2021 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 67% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
This could take some time, please wait.